E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma

E7386 sensitized tumors to lenvatinib, thereby enhancing survival in mice compared with either monotherapy. In patients, E7386 combined with lenvatinib promoted tumor shrinkage and, in parallel, activated ATF4 signaling.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2025-09-23
DOI
https://doi.org/10.1158/1078-0432.ccr-25-0725
Citations
1
Primary Topic
Peptidase Inhibition and Analysis
Type
article
Field-Weighted Citation Impact
1.05

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma

Agavni Mesropian, Roger Esteban-Fabró, Alka A. Potdar, Jialing Shen et al.
1 citations
Clinical Cancer Research
Peptidase Inhibition and Analysis
1.05
article

E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma

Agavni Mesropian, Roger Esteban-Fabró, Alka A. Potdar, Jialing Shen, Daniela Sia, Marta Piqué‐Gili, Albert Gris‐Oliver, Masafumi Ikeda, Jordi Abril‐Fornaguera, Ugne Balaseviciute, Masatoshi Kudo, Roser Pinyol, Katherine E. Lindblad, Ana Hernández de Sande, Judit Peix, Josep Maria Llovet, Ieva Keraite, Ernesto Guccione, Amaia Lujambio, Elisa Fernández‐Martínez, Marina Bárcena‐Varela, Júlia Huguet‐Pradell, Swan N. Thung, Martí Torres-Marcén, Takayuki Kimura, David Camell-Raventos
article en
1 citations

Abstract

E7386 sensitized tumors to lenvatinib, thereby enhancing survival in mice compared with either monotherapy. In patients, E7386 combined with lenvatinib promoted tumor shrinkage and, in parallel, activated ATF4 signaling.

Clinical Cancer ResearchVol. 31(23)
Institució Catalana de Recerca i Estudis Avançats (ES), Mount Sinai Hospital (US), Departament de Salut (ES), Institut d'Investigacions Biomèdiques de Barcelona (ES), Tisch Hospital (US), National Cancer Center Hospital East (JP), Eisai (United States) (US), Fundació Clínic per a la Recerca Biomèdica (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Eisai (Japan) (JP), Kindai University (JP), Icahn School of Medicine at Mount Sinai (US)
Georgia Clinical and Translational Science Alliance, Generalitat de Catalunya, Eisai, Ministerio de Ciencia e Innovación, Universitat de Barcelona, European Association for the Study of the Liver, Societat Catalana de Digestologia, National Institutes of Health, Chugai Pharmaceutical, Agència de Gestió d'Ajuts Universitaris i de Recerca, National Center for Advancing Translational Sciences
Openalex Percentile: Top 17%
Peptidase Inhibition and Analysis
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.